FDA approves UCB’s Cimzia in plaque psoriasis
The US FDA has approved a label extension for UCB’s Cimzia (certolizumab pegol) for adults with moderate-to-severe plaque psoriasis
X
FDA approves UCB’s Cimzia in plaque psoriasis
https://pharmaphorum.com/news/fda-ucbs-cimzia-plaque-psoriasis/
